The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with HCV genotype 1b
Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12402. [Epub ahead of print]
Abstract
BACKGROUND AND AIM:
The aim of this study was to clarify which or how factors could influence the probability of sustained virologic response (SVR) in 24-week telaprevir-based triple combination therapy for East Asian chronic hepatitis C patients infected with hepatitis C virus (HCV) genotype 1b.
METHODS:
Of 140 patients who were enrolled in this study, 137 received 12-week telaprevir combined with 24-week pegylated interferon alpha-2b plus ribavirin and were subjected to the analysis. Factors associated with SVR were analyzed by multiple logistic regression analysis.
RESULTS:
Of the 137 patients, 112 (82%) achieved SVR. Of 87 patients with IL28B single nucleotide polymorphism (SNP) rs8099917 genotype TT, 84 (97%) achieved SVR. By contrast, 28 of 50 (56%) patients with the genotype TG/GG had SVR (p=3.29×10-9 ). Fifty-three of 60 (88%) naïve patients and 50 of 54 (93%) prior relapsers achieved SVR. Nine of 13 (69%) prior partial responders and none of 10 (0%) prior null responders achieved SVR. Multivariable analysis identified four independent factors that were significantly associated with SVR: IL28B SNP rs8099917 genotype (p=6.90×10-5 ), preexistence of cirrhosis (p=3.99×10-3 ), prior treatment response (p=0.0126), and rapid virological response (p=0.0239).
CONCLUSIONS:
The IL28B SNP still remained informative as a predictor of SVR to 24-week telaprevir-based triple combination therapy for East Asian patients infected with HCV genotype 1b.